Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in San Diego, California and currently employs 949 full-time employees. The company went IPO on 2007-01-19. The firm is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The firm is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Industry: Biological Products, (No Diagnostic Substances) Peers: Alector Inc Kalaris Therapeutics Inc AnaptysBio Inc Anavex Life Sciences Corp CTI BIOPHARMA CORP Dyne Therapeutics, Inc RAPT Therapeutics, Inc. INTERCEPT PHARMACEUTICALS, INC. iTeos Therapeutics, Inc.